HeartFlow Analysis

The HeartFlow Analysis is a software device that provides a non-invasive, quantitative functional evaluation of coronary artery disease by analyzing CT DICOM data. It achieves this by creating a patient-specific 3D model of the coronary arteries and employing advanced physiological simulation, including a "Gen3 Solver", to calculate FFRct and other hemodynamic parameters, thereby aiding clinicians in diagnosis and treatment strategy.

The HeartFlow Analysis is a non-invasive software medical device designed for the clinical quantitative and qualitative analysis of coronary artery disease in clinically stable symptomatic patients. It processes previously acquired Computed Tomography (CT) DICOM data to generate a 3D computer model of the patient's coronary arteries. Utilizing this model, the software performs physiological simulations to compute FFRct, a mathematically derived quantity representing fractional flow reserve, along with other simulated hemodynamic data such as blood flow, pressure, and velocity. These outputs, presented in graphic and text formats, are intended to aid qualified clinicians in the assessment and treatment planning of coronary artery disease. The device is intended to support the functional evaluation of coronary artery disease and is to be used by clinicians in conjunction with the patient's clinical history and other diagnostic information. Its core technology includes semi-automated extraction of anatomical data from CT images, centerline detection, lumen boundary determination, and the ability to modify the anatomical model. The FFRct v3 iteration employs a "Gen3 Solver" with updated calculations for total coronary baseline flow and flow distribution. Validation studies for the device included stress testing and repeatability testing, with evaluations performed using previously acquired diagnostic images from clinical trials, ensuring the device's acceptability for its intended use.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. What specific algorithmic changes in the "Gen3 Solver" differentiate its flow and distribution calculations from the "Gen2 Solver," and how do these changes impact the accuracy or clinical utility of FFRct values?; How does the exposure of interim calculations, such as mass and volume, in FFRct v3 enhance a clinician's ability to assess model accuracy or understand the basis of the FFRct computation?; What were the specific quantitative results from the stress testing and repeatability testing for FFRct v3, particularly concerning the performance of the Gen3 solver compared to its predicate?; Given that the software analyzes "static coronary CT images," what are the known limitations in simulating dynamic physiological conditions, such as maximal hyperemia or varying cardiac outputs, and how are these addressed or accounted for in the FFRct calculation?; How does the semi-automated tool for extraction of anatomic data handle challenging cases, such as significant calcification, motion artifacts, or complex bifurcations in CT images, and what is the typical inter-observer variability in the resulting FFRct values after clinician review and potential model modification?